Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Platelet Aggregation | 5 | 2019 | 318 | 2.16 | Why? |
| Blood Platelets | 11 | 2019 | 1704 | 1.64 | Why? |
| Platelet Function Tests | 6 | 2018 | 231 | 1.54 | Why? |
| Adenosine Diphosphate | 4 | 2019 | 63 | 1.14 | Why? |
| Platelet Activation | 5 | 2019 | 660 | 1.01 | Why? |
| Platelet Aggregation Inhibitors | 10 | 2019 | 1671 | 1.00 | Why? |
| Purinergic P2Y Receptor Antagonists | 4 | 2019 | 206 | 0.97 | Why? |
| Thrombocytopenia | 3 | 2021 | 2093 | 0.88 | Why? |
| Acute Coronary Syndrome | 9 | 2019 | 2107 | 0.80 | Why? |
| Receptors, Purinergic P2Y12 | 2 | 2019 | 42 | 0.75 | Why? |
| Thrombocytosis | 1 | 2018 | 21 | 0.73 | Why? |
| ATP Binding Cassette Transporter 1 | 1 | 2017 | 17 | 0.72 | Why? |
| Citrates | 1 | 2017 | 37 | 0.69 | Why? |
| Venous Thrombosis | 4 | 2020 | 2739 | 0.69 | Why? |
| Mesenteric Ischemia | 1 | 2019 | 128 | 0.67 | Why? |
| Thrombosis | 6 | 2021 | 7504 | 0.66 | Why? |
| Venous Thromboembolism | 4 | 2020 | 4273 | 0.52 | Why? |
| Pulmonary Artery | 1 | 2020 | 803 | 0.52 | Why? |
| Hydrogen-Ion Concentration | 1 | 2017 | 993 | 0.51 | Why? |
| ADAMTS13 Protein | 1 | 2017 | 363 | 0.51 | Why? |
| Ventricular Remodeling | 1 | 2017 | 349 | 0.51 | Why? |
| Platelet Count | 5 | 2020 | 1381 | 0.49 | Why? |
| Purpura, Thrombotic Thrombocytopenic | 1 | 2017 | 284 | 0.48 | Why? |
| Pulmonary Embolism | 3 | 2020 | 4775 | 0.47 | Why? |
| Anticoagulants | 8 | 2021 | 9563 | 0.44 | Why? |
| von Willebrand Factor | 1 | 2017 | 668 | 0.43 | Why? |
| Vitamin K 1 | 1 | 2008 | 26 | 0.39 | Why? |
| Solid Phase Extraction | 1 | 2008 | 23 | 0.39 | Why? |
| Ticlopidine | 4 | 2017 | 193 | 0.38 | Why? |
| Heparin | 4 | 2021 | 2600 | 0.34 | Why? |
| Hyperhomocysteinemia | 1 | 2006 | 24 | 0.33 | Why? |
| Homocysteine | 2 | 2006 | 83 | 0.32 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2008 | 669 | 0.28 | Why? |
| Protein C | 1 | 2003 | 141 | 0.24 | Why? |
| Hemorrhage | 3 | 2019 | 3013 | 0.23 | Why? |
| Coronary Thrombosis | 2 | 2019 | 433 | 0.21 | Why? |
| ST Elevation Myocardial Infarction | 1 | 2017 | 3051 | 0.21 | Why? |
| Mutation | 2 | 2019 | 12376 | 0.21 | Why? |
| Aspirin | 2 | 2018 | 1043 | 0.20 | Why? |
| Factor V | 1 | 2019 | 52 | 0.20 | Why? |
| Complement C4 | 1 | 2019 | 86 | 0.19 | Why? |
| Colitis, Ischemic | 1 | 2019 | 116 | 0.19 | Why? |
| Blood Cells | 1 | 2019 | 104 | 0.18 | Why? |
| Tangier Disease | 1 | 2017 | 1 | 0.18 | Why? |
| Hypoalphalipoproteinemias | 1 | 2017 | 2 | 0.18 | Why? |
| Fasting | 1 | 2003 | 555 | 0.17 | Why? |
| Percutaneous Coronary Intervention | 3 | 2019 | 3646 | 0.17 | Why? |
| Prasugrel Hydrochloride | 1 | 2017 | 114 | 0.17 | Why? |
| Blood Platelet Disorders | 1 | 2017 | 44 | 0.17 | Why? |
| Hemostasis | 2 | 2020 | 811 | 0.16 | Why? |
| Platelet-Rich Plasma | 1 | 2017 | 91 | 0.16 | Why? |
| Internal Medicine | 1 | 2021 | 557 | 0.14 | Why? |
| Hemophilia A | 1 | 2020 | 362 | 0.14 | Why? |
| Microscopy, Electron | 1 | 2017 | 830 | 0.14 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.14 | Why? |
| Arterial Occlusive Diseases | 1 | 2018 | 363 | 0.13 | Why? |
| Cigarette Smoking | 1 | 2017 | 337 | 0.13 | Why? |
| Thromboembolism | 1 | 2006 | 2101 | 0.13 | Why? |
| Blood Specimen Collection | 1 | 2017 | 387 | 0.13 | Why? |
| Humans | 36 | 2021 | 930598 | 0.12 | Why? |
| Enoxaparin | 1 | 2020 | 1064 | 0.12 | Why? |
| Antiphospholipid Syndrome | 1 | 2019 | 533 | 0.12 | Why? |
| Drug-Eluting Stents | 1 | 2019 | 562 | 0.12 | Why? |
| Non-ST Elevated Myocardial Infarction | 1 | 2018 | 490 | 0.12 | Why? |
| Complement Activation | 1 | 2019 | 949 | 0.12 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2020 | 645 | 0.12 | Why? |
| Dose-Response Relationship, Drug | 2 | 2018 | 3776 | 0.11 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2020 | 1731 | 0.11 | Why? |
| Polymorphism, Genetic | 1 | 2018 | 1074 | 0.11 | Why? |
| Organizational Innovation | 1 | 2021 | 2468 | 0.10 | Why? |
| Coronary Vessels | 1 | 2017 | 914 | 0.10 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.10 | Why? |
| Risk Factors | 9 | 2021 | 71621 | 0.09 | Why? |
| Case-Control Studies | 3 | 2020 | 17671 | 0.09 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.09 | Why? |
| Hospitals, University | 1 | 2021 | 4173 | 0.09 | Why? |
| Homocystinuria | 1 | 2006 | 1 | 0.09 | Why? |
| Predictive Value of Tests | 2 | 2021 | 9537 | 0.08 | Why? |
| Male | 17 | 2021 | 367725 | 0.08 | Why? |
| Pyrazoles | 1 | 2017 | 1791 | 0.08 | Why? |
| Fibrinolytic Agents | 1 | 2018 | 1702 | 0.08 | Why? |
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2006 | 37 | 0.08 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.08 | Why? |
| Fluorescence | 1 | 2008 | 475 | 0.08 | Why? |
| Patient Care Team | 1 | 2021 | 3556 | 0.08 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.08 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.08 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.08 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.07 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.07 | Why? |
| Analysis of Variance | 1 | 2008 | 950 | 0.07 | Why? |
| Reference Standards | 1 | 2008 | 1163 | 0.07 | Why? |
| Myocardial Infarction | 2 | 2019 | 3361 | 0.07 | Why? |
| Aged | 14 | 2021 | 215776 | 0.07 | Why? |
| Genetic Predisposition to Disease | 1 | 2019 | 4027 | 0.07 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.07 | Why? |
| Italy | 4 | 2021 | 38444 | 0.07 | Why? |
| Point Mutation | 1 | 2006 | 481 | 0.06 | Why? |
| Lung Diseases | 1 | 2017 | 2361 | 0.06 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.06 | Why? |
| Ultrasonography | 1 | 2019 | 4409 | 0.06 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.06 | Why? |
| Treatment Outcome | 6 | 2020 | 51732 | 0.06 | Why? |
| Recurrence | 2 | 2017 | 3675 | 0.06 | Why? |
| Linear Models | 1 | 2008 | 1914 | 0.06 | Why? |
| Female | 14 | 2021 | 380317 | 0.06 | Why? |
| Biomarkers | 3 | 2020 | 23361 | 0.06 | Why? |
| C-Reactive Protein | 1 | 2018 | 7972 | 0.06 | Why? |
| Surgical Procedures, Operative | 1 | 2017 | 2662 | 0.05 | Why? |
| Adult | 7 | 2021 | 244371 | 0.05 | Why? |
| 6-Ketoprostaglandin F1 alpha | 1 | 2018 | 2 | 0.05 | Why? |
| In Vitro Techniques | 1 | 2003 | 1027 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
| Cyclic AMP | 1 | 2018 | 76 | 0.05 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.04 | Why? |
| Prothrombin Time | 1 | 2020 | 434 | 0.04 | Why? |
| Premedication | 1 | 2017 | 40 | 0.04 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 6653 | 0.04 | Why? |
| Vitamins | 1 | 2006 | 1208 | 0.04 | Why? |
| Complement C3 | 1 | 2019 | 271 | 0.04 | Why? |
| Young Adult | 3 | 2017 | 93724 | 0.04 | Why? |
| Survival Rate | 2 | 2021 | 9206 | 0.04 | Why? |
| Perfusion | 1 | 2017 | 254 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Janus Kinase 1 | 1 | 2017 | 254 | 0.04 | Why? |
| Janus Kinase 2 | 1 | 2017 | 218 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2020 | 10649 | 0.04 | Why? |
| Product Surveillance, Postmarketing | 1 | 2017 | 189 | 0.04 | Why? |
| Prospective Studies | 4 | 2018 | 43301 | 0.04 | Why? |
| Risk Assessment | 4 | 2021 | 25439 | 0.04 | Why? |
| Animals | 3 | 2018 | 78931 | 0.04 | Why? |
| Confidence Intervals | 1 | 2017 | 744 | 0.04 | Why? |
| Antibiotic Prophylaxis | 1 | 2017 | 399 | 0.03 | Why? |
| ROC Curve | 2 | 2021 | 6024 | 0.03 | Why? |
| Thrombophilia | 1 | 2006 | 1935 | 0.03 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.03 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2017 | 782 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Erythrocytes | 1 | 2019 | 617 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.03 | Why? |
| Nitriles | 1 | 2017 | 1053 | 0.03 | Why? |
| Cooperative Behavior | 1 | 2020 | 1216 | 0.03 | Why? |
| Herpes Zoster | 1 | 2017 | 331 | 0.03 | Why? |
| Secondary Prevention | 1 | 2017 | 762 | 0.03 | Why? |
| Purinergic P2 Receptor Antagonists | 1 | 2010 | 7 | 0.03 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.03 | Why? |
| Incidence | 3 | 2017 | 25622 | 0.03 | Why? |
| Mycoses | 1 | 2017 | 589 | 0.03 | Why? |
| Coronary Artery Disease | 2 | 2019 | 2570 | 0.03 | Why? |
| Pyrimidines | 1 | 2017 | 1557 | 0.02 | Why? |
| Drug Resistance | 1 | 2010 | 395 | 0.02 | Why? |
| Hypertension, Pulmonary | 1 | 2017 | 970 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Adolescent | 2 | 2017 | 86841 | 0.02 | Why? |
| Angioplasty, Balloon, Coronary | 1 | 2010 | 365 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Patient Selection | 1 | 2020 | 4560 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Intubation, Intratracheal | 1 | 2021 | 3962 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2017 | 4002 | 0.02 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Electrocardiography | 1 | 2017 | 3957 | 0.02 | Why? |
| Stents | 1 | 2010 | 916 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |
| Lung | 1 | 2017 | 31049 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |
Cattaneo's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(183)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(133)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_